Yasser Ged

13PUBLICATIONS

102CO-AUTHORS

Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Solid tumoursEpidemiological modelling

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (13)

Sort by Publication Date:

|Jun 26, 2026

Peripheral Th17 immune signature associates with excellent response to anti-PD1/anti-PD-L1 therapy across solid tumors.

|Jun 18, 2026

1H MR-based detection of human plasma metabolic alterations in clear cell renal cell carcinoma.

|Sep 15, 2025

Immune Activation Signatures Associated with Fatigue in Cancer Patients Undergoing Immune Checkpoint Inhibitor Therapy.

Howard L Li, Soren Charmsaz, Mari Nakazawa

|Mar 27, 2025

Anti-CTLA4 Therapy Leads to Early Expansion of a Peripheral Th17 Population and Induction of Th1 Cytokines.

Mari Nakazawa, Soren Charmsaz, Elsa Hallab

|Mar 25, 2025

Clear-Cell Renal Cell Carcinoma Molecular Subtypes Differ by African and European Genetic Similarity.

Roy Elias, Thomas Nirschl, Michael Rezaee

|Feb 04, 2025

Multi-institutional Analysis of Immune-Oncology Combination Therapy for Metastatic MiT Family Translocation Renal Cell Carcinoma.

Yasser Ged, Amina Touma, Luis Meza Contreras

Pageof 3

Frequent Collaborators

Mark Yarchoan

Soren Charmsaz

James M Leatherman

Jeannie Hoffman-Censits

Evan J Lipson

Howard L Li

Madelena Brancati

Chester Kao

Christopher Thoburn

Mari Nakazawa

Frequent Collaborators

Mark Yarchoan

Soren Charmsaz

James M Leatherman

Jeannie Hoffman-Censits